These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 2881870)

  • 1. [The dopamine receptor. Target of various diseases].
    Herschel M
    Fortschr Med; 1987 Feb; 105(5):86-8. PubMed ID: 2881870
    [No Abstract]   [Full Text] [Related]  

  • 2. The antiparkinsonian activity of dopamine agonists and their interaction with central dopamine receptor subtypes.
    Goldstein M; Lieberman AN; Takasugi N; Shimizu Y; Kuga S
    Adv Neurol; 1990; 53():101-6. PubMed ID: 1978511
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuropsychiatric implications of drugs acting on dopamine receptors: the effect of apomorphine.
    Corsini GU; Bernardi F; Marrosu F; Gessa GL
    Prog Clin Biol Res; 1980; 39():225-37. PubMed ID: 6447296
    [No Abstract]   [Full Text] [Related]  

  • 4. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
    Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G
    Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067
    [No Abstract]   [Full Text] [Related]  

  • 5. Dopamine: pharmacologic and therapeutic aspects.
    Velasco M; Luchsinger A
    Am J Ther; 1998 Jan; 5(1):37-43. PubMed ID: 10099036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potentials of centrally acting dopamine and alpha 2-adrenoreceptor agonists.
    Goldstein M; Engel J; Lieberman A; Regev I; Bystritsky A; Mino S
    J Neural Transm Suppl; 1983; 18():257-63. PubMed ID: 6135744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine agonists, sleep disorders, and driving in Parkinson's disease.
    Uitti RJ; Wszolek ZK
    Adv Neurol; 2003; 91():343-9. PubMed ID: 12442692
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological basis of therapeutics: dopamine receptors.
    Heikkila RE
    J Med Soc N J; 1984 Dec; 81(12):1084-6. PubMed ID: 6150999
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine receptor pharmacology.
    Seeman P; Van Tol HH
    Curr Opin Neurol Neurosurg; 1993 Aug; 6(4):602-8. PubMed ID: 8104554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alpha-2-agonists in psychiatry--a review].
    Grenhoff J; Svensson TH
    Lakartidningen; 1988 Jun; 85(25):2259-61. PubMed ID: 2898579
    [No Abstract]   [Full Text] [Related]  

  • 11. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

  • 12. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy.
    Guttman M; Seeman P
    Adv Neurol; 1987; 45():51-7. PubMed ID: 2950731
    [No Abstract]   [Full Text] [Related]  

  • 14. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptors--the present state of research and perspectives.
    Wolfarth S; Ossowska K
    Pol J Pharmacol; 1995; 47(3):207-18. PubMed ID: 8714754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights in Parkinson's disease therapy: can levodopa-induced dyskinesia ever be manageable.
    Hadj Tahar A; Grondin R; Grégoire L; Calon F; Di Paolo T; Bédard PJ
    Adv Neurol; 2003; 91():51-64. PubMed ID: 12442663
    [No Abstract]   [Full Text] [Related]  

  • 17. The visual system in Parkinson's disease.
    Bodis-Wollner I; Tagliati M
    Adv Neurol; 1993; 60():390-4. PubMed ID: 8420159
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of dopamine receptors in neurological drug treatment.
    Rinne UK
    Ann Clin Res; 1988; 20(5):334-9. PubMed ID: 3218905
    [No Abstract]   [Full Text] [Related]  

  • 19. Medications for Parkinson's disease.
    Whitney CM
    Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
    [No Abstract]   [Full Text] [Related]  

  • 20. [Neuroleptic malignant syndrome (dopamine-dependent malignant hyperthermia). 4 different cases].
    Truong DD; Sczesni B; Fahn S; Gross J; Donovan K; van Bakel A; Wiley MK
    Nervenarzt; 1988 Feb; 59(2):103-9. PubMed ID: 2896306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.